[1]徐萌,李慧源.联合检测血清HE4和CA125对卵巢恶性肿瘤的诊断价值[J].中国计划生育和妇产科,2011,(03):0.
　XU Meng,LI Hui-yuan ..[J].Chinese Journal of Family Planning & Gynecotokology,2011,(03):0.
点击复制

联合检测血清HE4和CA125对卵巢恶性肿瘤的诊断价值

分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

Author(s):: XU Meng1; LI Hui-yuan2 1.; Department of Gynaecology and Obstetrics,Changsha the Eighth Hospital,Changsha Hu’nan 410001,P.R.China;2.Golden Inspection Agency of Changsha City,Changsha Hu’nan 410205,P.R.China

摘要:: 目的探讨血清中人附睾蛋白4(human epididymis protein 4,HE4)和糖链抗原-125(carbohydrate antigen 125,CA125)对卵巢恶性肿瘤的诊断价值。方法测定123例女性血清标本,其中卵巢恶性肿瘤34例,卵巢良性疾病39例,健康体检女性50例,用酶联免疫分析法(enzyme-linked immunosorbentassay,ELISA)和电化学发光法(electrochemiluminescence immunoassay,ECLIA)分别检测血清HE4和CA125水平。结果卵巢恶性肿瘤组血清HE4和CA125水平明显高于其他两组,差异有统计学意义(P<0.05);卵巢良性疾病组和健康对照组HE4比较差异无统计学意义(P>0.05)。以卵巢良性疾病作参照,单独检测血清HE4水平对卵巢恶性肿瘤诊断的敏感性为61.8%,低于单独检测CA125的73.5%;但特异性96.6%,高于CA125的80.9%。以二者其中之一高于参考值即视为阳性,联合检测血清HE4和CA125水平对卵巢恶性肿瘤诊断的敏感性94.1%,特异性80.9%,阴性预测值97.3%。结论检测血清HE4和CA125水平可明显提高卵巢恶性肿瘤诊断的准确率,并有助于卵巢良、恶性疾病的鉴别诊断。

[1]李海燕.血清人附睾蛋白4和糖类抗原125在卵巢上皮性癌治疗前后的变化及对近期预后的影响[J].中国计划生育和妇产科,2017,(12):61.
　LI Hai-yan.Changes of serum HE4 and CA125 before and after treatment of epithelial ovarian cancer and their effects on short-term prognosis[J].Chinese Journal of Family Planning & Gynecotokology,2017,(03):61.
[2]赵长燕*,贺红梅,张明慧.血清DKK-4、nidogen-2与HE 4在卵巢浆液性肿瘤患者中的表达及其临床意义[J].中国计划生育和妇产科,2019,(2):89.
　ZHAO Chang-yan*,HE Hong-mei,ZHANG Ming-hui.Clinical value of DKK-4 and nidogen-2 combined with HE 4 in the diagnosis of serous ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2019,(03):89.

更新日期/Last Update: 2011-06-30